These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34838583)

  • 1. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
    Cochin M; Touret F; Driouich JS; Moureau G; Petit PR; Laprie C; Solas C; de Lamballerie X; Nougairède A
    Antiviral Res; 2022 Jan; 197():105212. PubMed ID: 34838583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
    Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
    Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
    Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
    Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
    Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
    Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
    Hache G; Rolain JM; Gautret P; Deharo JC; Brouqui P; Raoult D; Honoré S
    Microb Drug Resist; 2021 Mar; 27(3):281-290. PubMed ID: 33729874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.
    Scherrmann JM
    AAPS J; 2020 Jun; 22(4):86. PubMed ID: 32533263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models.
    Rosenke K; Jarvis MA; Feldmann F; Schwarz B; Okumura A; Lovaglio J; Saturday G; Hanley PW; Meade-White K; Williamson BN; Hansen F; Perez-Perez L; Leventhal S; Tang-Huau TL; Callison J; Haddock E; Stromberg KA; Scott D; Sewell G; Bosio CM; Hawman D; de Wit E; Feldmann H
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33090972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
    Touret F; Driouich JS; Cochin M; Petit PR; Gilles M; Barthélémy K; Moureau G; Mahon FX; Malvy D; Solas C; de Lamballerie X; Nougairède A
    Antiviral Res; 2021 Sep; 193():105137. PubMed ID: 34265358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia.
    Purwati ; Miatmoko A; Nasronudin ; Hendrianto E; Karsari D; Dinaryanti A; Ertanti N; Ihsan IS; Purnama DS; Asmarawati TP; Marfiani E; Yulistiani ; Rosyid AN; Wulaningrum PA; Setiawan HW; Siswanto I; Tri Puspaningsih NN
    PLoS One; 2021; 16(6):e0252302. PubMed ID: 34143818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.
    Ni Y; Liao J; Qian Z; Wu C; Zhang X; Zhang J; Xie Y; Jiang S
    Bioorg Med Chem; 2022 Jan; 53():116523. PubMed ID: 34875467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
    Million M; Roussel Y; Gautret P; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106240. PubMed ID: 33408019
    [No Abstract]   [Full Text] [Related]  

  • 13. Antimalarials as Antivirals for COVID-19: Believe it or Not!
    Saha BK; Bonnier A; Chong W
    Am J Med Sci; 2020 Dec; 360(6):618-630. PubMed ID: 32950177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
    Kang CK; Seong MW; Choi SJ; Kim TS; Choe PG; Song SH; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2020 Jul; 35(4):782-787. PubMed ID: 32460458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment.
    Drancourt M; Cortaredona S; Melenotte C; Amrane S; Eldin C; La Scola B; Parola P; Million M; Lagier JC; Raoult D; Colson P
    Viruses; 2021 May; 13(5):. PubMed ID: 34065871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann.
    Gautret P; Hoang VT; Colson P; Raoult D
    Int J Antimicrob Agents; 2021 Mar; 57(3):106306. PubMed ID: 33596459
    [No Abstract]   [Full Text] [Related]  

  • 17. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.
    Rosenke K; Hansen F; Schwarz B; Feldmann F; Haddock E; Rosenke R; Barbian K; Meade-White K; Okumura A; Leventhal S; Hawman DW; Ricotta E; Bosio CM; Martens C; Saturday G; Feldmann H; Jarvis MA
    Nat Commun; 2021 Apr; 12(1):2295. PubMed ID: 33863887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.
    Mori N; Katayama M; Nukaga S
    J Microbiol Immunol Infect; 2021 Feb; 54(1):109-112. PubMed ID: 33054978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
    Mégarbane B; Scherrmann JM
    J Clin Pharmacol; 2020 Jul; 60(7):808-814. PubMed ID: 32434282
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
    Jordaan P; Dumotier B; Traebert M; Miller PE; Ghetti A; Urban L; Abi-Gerges N
    Toxicol Sci; 2021 Apr; 180(2):356-368. PubMed ID: 33483756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.